These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25284254)

  • 1. Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol.
    Fernández-Tejada A; Chea EK; George C; Gardner JR; Livingston PO; Ragupathi G; Tan DS; Gin DY
    Bioorg Med Chem; 2014 Nov; 22(21):5917-23. PubMed ID: 25284254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis.
    Fernández-Tejada A; Tan DS; Gin DY
    Acc Chem Res; 2016 Sep; 49(9):1741-56. PubMed ID: 27568877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semisynthesis of Analogues of the Saponin Immunoadjuvant QS-21.
    Fernández-Tejada A; Walkowicz WE; Tan DS; Gin DY
    Methods Mol Biol; 2017; 1494():45-71. PubMed ID: 27718185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid tucaresol as an adjuvant for methamphetamine vaccine development.
    Collins KC; Schlosburg JE; Lockner JW; Bremer PT; Ellis BA; Janda KD
    Chem Commun (Camb); 2014 Apr; 50(31):4079-81. PubMed ID: 24615284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploiting structure-activity relationships of QS-21 in the design and synthesis of streamlined saponin vaccine adjuvants.
    Ghirardello M; Ruiz-de-Angulo A; Sacristan N; Barriales D; Jiménez-Barbero J; Poveda A; Corzana F; Anguita J; Fernández-Tejada A
    Chem Commun (Camb); 2020 Jan; 56(5):719-722. PubMed ID: 31833496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants.
    Marty-Roix R; Vladimer GI; Pouliot K; Weng D; Buglione-Corbett R; West K; MacMicking JD; Chee JD; Wang S; Lu S; Lien E
    J Biol Chem; 2016 Jan; 291(3):1123-36. PubMed ID: 26555265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probes.
    Chea EK; Fernández-Tejada A; Damani P; Adams MM; Gardner JR; Livingston PO; Ragupathi G; Gin DY
    J Am Chem Soc; 2012 Aug; 134(32):13448-57. PubMed ID: 22866694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QS-21 Adjuvant: Laboratory-Scale Purification Method and Formulation Into Liposomes.
    Brunner L; Barnier-Quer C; Collin N
    Methods Mol Biol; 2017; 1494():73-86. PubMed ID: 27718186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and Evaluation of QS-7-Based Vaccine Adjuvants.
    Wang P; Škalamera Đ; Sui X; Zhang P; Michalek SM
    ACS Infect Dis; 2019 Jun; 5(6):974-981. PubMed ID: 30920199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review.
    Lacaille-Dubois MA
    Phytomedicine; 2019 Jul; 60():152905. PubMed ID: 31182297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent response of QS-21 as a vaccine adjuvant in the skin when delivered with the Nanopatch, resulted in adjuvant dose sparing.
    Ng HI; Fernando GJ; Depelsenaire AC; Kendall MA
    Sci Rep; 2016 Jul; 6():29368. PubMed ID: 27404789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a minimal saponin vaccine adjuvant based on QS-21.
    Fernández-Tejada A; Chea EK; George C; Pillarsetty N; Gardner JR; Livingston PO; Ragupathi G; Lewis JS; Tan DS; Gin DY
    Nat Chem; 2014 Jul; 6(7):635-43. PubMed ID: 24950335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and Evaluation of a QS-17/18-Based Vaccine Adjuvant.
    Wang P; Škalamera Đ; Sui X; Zhang P; Michalek SM
    J Med Chem; 2019 Feb; 62(3):1669-1676. PubMed ID: 30656932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acylated and deacylated quillaja saponin-21 adjuvants have opposite roles when utilized for immunization of C57BL/6 mice model with MOG
    Heidari AR; Boroumand-Noughabi S; Nosratabadi R; Lavi Arab F; Tabasi N; Rastin M; Mahmoudi M
    Mult Scler Relat Disord; 2019 Apr; 29():68-82. PubMed ID: 30685444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer.
    Ragupathi G; Gardner JR; Livingston PO; Gin DY
    Expert Rev Vaccines; 2011 Apr; 10(4):463-70. PubMed ID: 21506644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
    Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO
    Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structure verification of the vaccine adjuvant QS-7-Api. Synthetic access to homogeneous Quillaja saponaria immunostimulants.
    Deng K; Adams MM; Gin DY
    J Am Chem Soc; 2008 May; 130(18):5860-1. PubMed ID: 18410100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Aapi.
    Kim YJ; Wang P; Navarro-Villalobos M; Rohde BD; Derryberry J; Gin DY
    J Am Chem Soc; 2006 Sep; 128(36):11906-15. PubMed ID: 16953631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The predominant Quillaja Saponaria fraction, QS-18, is safe and effective when formulated in a liposomal murine cancer peptide vaccine.
    Zhou S; Song Y; Nilam A; Luo Y; Huang WC; Long MD; Lovell JF
    J Control Release; 2024 May; 369():687-695. PubMed ID: 38575073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Foamy matters: an update on
    Magedans YV; Yendo AC; Costa F; Gosmann G; Fett-Neto AG
    Future Med Chem; 2019 Jun; 11(12):1485-1499. PubMed ID: 31304830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.